SCHEMBL1698196

SCHEMBL1698196

CCCC(C)C1CCCc2cccnc21

nearest known ligand 0.43

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 17/20 0.43
KCNH2 Q12809 1/20 0.39
CYP2D6 P10635 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1698226 0.96 CXCR4 (0.41) CXCR4KCNH2
SCHEMBL1701122 0.92 CXCR4 (0.38) CXCR4KCNH2
SCHEMBL1698219 0.92 DRD2 (0.38) CXCR4KCNH2
SCHEMBL1698222 0.89 CXCR4 (0.44) CXCR4KCNH2CYP2D6
SCHEMBL1698199 0.88 OPRL1 (0.36) CXCR4KCNH2
SCHEMBL12070440 0.87 CXCR4 (0.41) CXCR4KCNH2CYP2D6
SCHEMBL1698240 0.82 CXCR4 (0.45) CXCR4KCNH2CYP2D6
SCHEMBL19435835 0.82 CXCR4 (0.40) CXCR4KCNH2CYP2D6
SCHEMBL1698217 0.81 CXCR4 (0.42) CXCR4KCNH2CYP2D6
SCHEMBL1698223 0.80 OPRL1 (0.40) CXCR4KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8933231-B2 Organic compounds GIVAUDAN SA 2015-01-13 US claimed
CN-102946741-B Organic compounds GIVAUDAN SA 2014-05-14 CN claimed
US-20130129655-A1 Organic Compounds GIVAUDAN SA (CH) 2013-05-23 US claimed
EP-2584916-A1 ORGANIC COMPOUNDS Givaudan SA (CH) 2013-05-01 EP claimed
WO-2011160254-A1 ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2011-12-29 WO claimed
WO-2011161163-A1 ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2011-12-29 WO claimed
CN-107072911-B Malodor reducing compositions 奇华顿股份有限公司 2020-12-29 CN disclosed
US-20170290757-A1 MALODOR REDUCING COMPOSITIONS GIVAUDAN S.A. (CH) 2017-10-12 US disclosed
US-8933231-B2 Organic compounds GIVAUDAN SA 2015-01-13 US disclosed
US-8933231-B2 Organic compounds GIVAUDAN SA 2015-01-13 US disclosed
US-8933231-B2 Organic compounds GIVAUDAN SA 2015-01-13 US disclosed
CN-102946741-B Organic compounds GIVAUDAN SA 2014-05-14 CN disclosed
US-20130129655-A1 Organic Compounds GIVAUDAN SA (CH) 2013-05-23 US disclosed
US-20130129655-A1 Organic Compounds GIVAUDAN SA (CH) 2013-05-23 US disclosed
US-20130129655-A1 Organic Compounds GIVAUDAN SA (CH) 2013-05-23 US disclosed
EP-2584916-A1 ORGANIC COMPOUNDS Givaudan SA (CH) 2013-05-01 EP disclosed
WO-2011161163-A1 ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2011-12-29 WO disclosed
WO-2011160254-A1 ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2011-12-29 WO disclosed
WO-2011160254-A1 ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2011-12-29 WO disclosed
WO-2011161163-A1 ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2011-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130129655-A1 Organic Compounds C9, C5, TRPA1 CXCR4 1601/4885KCNH2 165/4885CYP2D6 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.